A new photobiomodulation therapy to treat oral mucositis
The First FDA Authorized Device for Radiation-Induced Oral Mucositis
Benefits to Physicians
- Supports oral mucositis severity reduction
- Helps preserve swallowing function
- Supports treatment tolerance
Benefits to Patients
- Less severe oral mucositis
- Helps maintain ability to eat and drink
- Supports comfort during therapy
For Hospitals
- Supports patient function during treatment
- Enhances supportive oncology care
- Supports patient experience
For Payors
- Supports management of treatment toxicity
- Supports continuity of care
- Supports functional outcomes
What’s New at MuReva Phototherapy?
American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
Obtaining this CPT code is an initial step to achieving reimbursement for the use of MuReva Phototherapy’s Photobiomodulation Therapy Device when it becomes commercially available Brecksville, Ohio (December 16, 2025) - MuReva Phototherapy, an emerging leader...
MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company’s LED-based Photobiomodulation Therapy Device
Study confirmed the safety and the ability of the company’s LED-based photobiomodulation therapy breakthrough device technology to reduce severity of oral mucositis in patients with head and neck cancer undergoing radiation therapy Brecksville, Ohio (October...
MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation (PBM) Device during the ASTRO 2023 Annual Meeting
MuReva Phototherapy presented data from a pilot prospective study of the company's Intraoral Photobiomodulation (PBM) Device during the the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting held from October 1-4, 2023 in San Diego, California. The...
MuReva Phototherapy presents data from pilot study of company’s photobiomodulation device during 2023 MASCC Annual Meeting
MuReva Phototherapy presented data from a pilot trial incorporating the us a the company's LED=based intraoral Photobiomodulation (PBM) device for daily use in head and neck cancer patients undergoing radiation therapy during the 2023 Annual Meeting of the...
